Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
December 14, 2020
Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial
X Melody Qu, Yujie Chen, Gregory S Zaric, et al.
Clinical Lung Cancer
|
June 5, 2014
An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer
Allison B Ashworth, Suresh Senan, David A Palma, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 3, 2024
Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: Long-Term Clinical Outcomes
Vivian S Tan, Rohann J M Correa, Timothy K Nguyen, et al.
BMC Cancer
|
July 8, 2022
Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial
Edward Yu, Alison L Allan, Michael Sanatani, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 4, 2015
Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model
Alexander V Louie, Cornelis J A Haasbeek, Sahar Mokhles, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 4, 2025
American Radium Society Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-Small Cell Lung Cancer Executive Summary
Charles B Simone, Arya Amini, Indrin J Chetty, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 13, 2022
Functional Lung Avoidance for Individualized Radiation Therapy: Results of a Double-Masked, Randomized Controlled Trial
Brian P Yaremko, Dante P I Capaldi, Khadija Sheikh, et al.
Lancet (London, England)
|
April 16, 2019
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A Palma, Robert Olson, Stephen Harrow, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 1, 2022
Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes
Stephen Harrow, David A Palma, Robert Olson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 13, 2024
Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET)
Meredith E Giuliani, Edith Filion, Sergio Faria, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
International Journal of Radiation Oncology, Biology, Physics
|
December 14, 2020
Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial
X Melody Qu, Yujie Chen, Gregory S Zaric, et al.
Clinical Lung Cancer
|
June 5, 2014
An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer
Allison B Ashworth, Suresh Senan, David A Palma, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 3, 2024
Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: Long-Term Clinical Outcomes
Vivian S Tan, Rohann J M Correa, Timothy K Nguyen, et al.
BMC Cancer
|
July 8, 2022
Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial
Edward Yu, Alison L Allan, Michael Sanatani, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 4, 2015
Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model
Alexander V Louie, Cornelis J A Haasbeek, Sahar Mokhles, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 4, 2025
American Radium Society Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-Small Cell Lung Cancer Executive Summary
Charles B Simone, Arya Amini, Indrin J Chetty, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 13, 2022
Functional Lung Avoidance for Individualized Radiation Therapy: Results of a Double-Masked, Randomized Controlled Trial
Brian P Yaremko, Dante P I Capaldi, Khadija Sheikh, et al.
Lancet (London, England)
|
April 16, 2019
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A Palma, Robert Olson, Stephen Harrow, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 1, 2022
Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes
Stephen Harrow, David A Palma, Robert Olson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 13, 2024
Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET)
Meredith E Giuliani, Edith Filion, Sergio Faria, et al.
Page
of 9